GAITHERSBURG, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an informatics and genomic analysis company, announces the completion of its multi-drug resistant organisms (MDRO) health outcomes study with Intermountain Healthcare. It was a collaboration between Intermountain Healthcare and Enterprise Analysis Corporation (EAC) in a retrospective study to explore multi-drug resistant organisms and Clostridium difficile trends throughout the Intermountain Healthcare System over an 8-year period (2008-2015). The study was requested and funded by OpGen.
The objectives of the study included:
- Examine the antibiotic resistance burden within the Intermountain Healthcare System and associated epidemiology;
- Establish the timeliness by which antibiotic resistance has been identified in the microbiology laboratories using conventional culture methods;
- Explore the relationship between microbiology results turnaround time and effective antibiotic use;
- Estimate the possible benefits of a shorter turnaround time on duration of empiric, and time to effective, antibiotic therapy in patients with MDRO infections;
- Project improvements in medical outcomes;
- Assess the possible beneficial impact of such improved diagnostics on healthcare costs.
“This comprehensive retrospective study, conducted by Intermountain Healthcare, should provide significant insights into how healthcare systems can reduce infections and improve health outcomes,” said Rob Lilley, Chief Commercial Officer at OpGen.
Given the complexity of the targets in this study – Gram negative organisms such as E. coli, Klebsiella, Acinetobacter, Enterobacter, Pseudomonas that were resistant to three or more classes of antibiotics, and additional pathogens such as VRE, MRSA, and C. difficile – Intermountain Healthcare narrowed down their sample patient population from 900,000 to a total of 12,750 inpatient MDRO encounters, after applying the study criteria. EAC conducted a statistical analysis of the data for this study.
“We are proud to have supported a study of this magnitude and to work with one of the nation's most respected integrated health networks,” said Evan Jones, Chairman and CEO of OpGen. “The next phase of the collaboration will focus on the use of OpGen’s technologies to help guide clinical decisions with a goal of improving patient outcomes and reducing costs associated with drug-resistant pathogen and C. difficile infections.”
OpGen is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. For more information, visit www.opgen.com.
About Intermountain Healthcare
Intermountain Healthcare is a Utah-based, not-for-profit system of 22 hospitals, 185 clinics, a Medical Group with over 1,400 employed physicians and advanced practice clinicians, a health plans division called SelectHealth, and other health services. Helping people live the healthiest lives possible, Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit intermountainhealthcare.org.
This press release includes statements relating to the company's support of the Intermountain Healthcare retrospective study and the next steps involving the use of the company’s Acuitas MDRO, Acuitas Lighthouse and QuickFISH products and services to help guide clinical decisions regarding MDROs These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Kim Sutton Golodetz
MacDougall Biomedical Communications